Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction in long-term care, as 4Q25 net product revenue reached $2.5M and FY25 total revenue reached $10.2M, including $6.8M of ZUNVEYL sales. More importantly, demand indicators continued to inflect, with bottles dispensed rising 62% q/q to 4,941 with December alone reaching a record 1,859 bottle. Repeat ordering remained strong, supporting management’s view that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols.